Our Patient Value Strategy

Our Patient Value Strategy

Our Patient Value Strategy, launched in 2015, has been the driver of UCB’s performance. Our operational model puts patients and their individual experiences at the heart of everything we do – from discovery to development to delivery. We leverage patient insights to inform our science and build solutions we can deliver to patients. It is through this continuous dialogue with patients that we can develop innovative and differentiated solutions that deliver our ambition for patients in specific patient populations.

UCB’s operational model puts the patient at the heart of our activities and decisions
Patient Value Strategy (graphic)

Our strategic goal is to be the leader in specific patient populations by 2025

Our Patient Value Strategy is the foundation for our goal to lead in specific patient populations by 2025 and guides us on our journey to become the patient-preferred biopharma leader. This future goal is supported by three strategic imperatives:

1. Keep patients and innovation at the core of our activities

UCB is “Inspired by patients and driven by science”. To create value for patients, we must maintain our focus on patients expressed unmet needs and continue developing and investing in state-of-the-art scientific platforms and medical advances.

2. Remain open and connected to the external world

In a dynamic world with many new frontiers in science and technology, we are embracing the latest medical science, as well as advances in artificial intelligence and digital health, aware of societal challenges around us. Our research and our partnerships are key to delivering on the promise of these developments.

3. Truly leverage our leadership & capabilities

UCB has a strong heritage in our focus areas of immunology and neurology. We will unlock the full potential of our world-leading expertise in these areas while continuing to build our patient value-based culture, leadership and strategic capabilities.

We aim to create value for specific patient populations, starting with a unique understanding of biology and the presentation of disease. It’s about understanding the patients deeply.

Emmanuel Caeymaex, Executive Vice President Immunology Solutions & Head U.S.

To reach our goal, we developed a long-term strategy with three strategic phases:

  • Grow and Prepare” from 2014-2018,
  • Accelerate and Expand” starting in 2019 (2019-2021) and finally 
  • “Breakthrough and Lead” in specific populations by 2025 (2021-2025).

In 2019, we entered the first year of this phase. As we look to the future, we will be navigating through important milestones and changes that could bring several new differentiated solutions to patients with severe diseases – consistent with our ambition for patients.

An overview of the three phases of our patient value strategy was outlined in our 2018 Integrated Annual Report.

Our Patient Value Strategy and organizational model are evolving to support us on our path towards our strategic goal

During the summer of 2019, we renewed our commitments to people with severe diseases and society and adapted our organization and our ways of working. Our new organization will help us to further embrace the opportunities ahead of us and adapt to internal and external changes so we can deliver on our goal.

Importantly, we are conducting a digital business transformation to fully embrace how digital technology is profoundly impacting the way healthcare and medicines are developed, delivered and experienced by healthcare professionals, payers and patients. The integration of sustainability into our strategy is also helping us improve our societal impact while ensuring that we continue to perform well as a company.

To learn more about how we are organized and the role of our employees in value creation visit the Our People section.

Relevant GRI Indicators

102-7 gri-id7:102-7